[A24-62] Selpercatinib (thyroid cancer) - Benefit assessment according to § 35a Social Code Book V
Last updated 15.08.2024
Project no.:
A24-62
Commission:
Commission awarded on 15.05.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Patients with advanced rearranged during transfection (RET) fusion-positive thyroid cancer
Result of dossier assessment:
- Adults and adolescents 12 years and older with radioiodine-refractory thyroid cancer, first-line treatment: added benefit not proven
- Adolescents 12 years and older after previous therapy with a protein kinase inhibitor: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A24-62_en
| Project no. | Title | Status |
|---|---|---|
| A21-29 | Selpercatinib (RET fusion-positive thyroid cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-28 | Selpercatinib (RET mutant medullary thyroid cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-27 | Selpercatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-65 | Selpercatinib (advanced NSCLC with RET fusion) – Benefit assessment according to § 35a SGB V | Commission completed |
| A22-106 | Selpercatinib (thyroid cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-63 | Selpercatinib (solid tumours) - Benefit assessment according to § 35a Social Code Book V | Commission completed |